How to Choose a PR agency for Diagnostics companies

By Aidan Sowa, CEO and Founder, Frontier Industries | October 2026

Clinical laboratories ran on quiet competence for decades. A test worked, a result came back, nobody wrote a headline. Then home testing put your category on kitchen counters, a pandemic put it on front pages, and regulators spent two years arguing in public about who governs a test built inside one laboratory. This guide gives you one filter for agency selection: hire the team that can explain your evidence, your oversight and your limits in language a patient, a payer and a judge would each accept. In diagnostics, credibility is the product everything else advertises.

I. Discrimen

A result is not a diagnosis, and your agency has to know the distance between them

Diagnostics rests on three separate claims that weak communicators merge into one. Analytical validity asks whether the test measures what it targets, accurately and repeatedly. Clinical validity asks whether that measurement tracks a condition. Clinical utility asks the hardest question: does knowing the result change a decision and improve an outcome. Each claim needs different evidence, and each fails in a different way.

An agency that writes "detects cancer early" off a study that showed analytical sensitivity has not made a wording error. It has exposed you to regulators, plaintiff firms and every journalist who covers this beat. Your first interview test is vocabulary: ask candidates to define those three claims using your own test as the example. The ones who hesitate are the ones who will cost you.

Three kinds of proof hold up a test. Confuse them in public and the correction becomes the story.

This is not pedantry, and your agency should be able to show you the practical difference with a headline. A test can be analytically superb, detecting a marker at vanishing concentrations, and still change nothing for patients if the marker does not discriminate between who needs treatment and who does not. Consumer marketing collapses those steps because collapse sells. Every collapse is a debt. It comes due when a clinician writes a letter, a competitor files a complaint, or a national newspaper runs the explainer your own team should have published first. The agencies worth hiring write the three claims as three sentences, each with its study attached, and refuse to let design merge them.

II. Machina

Your oversight framework became a moving target, and the public watched it move

For years, laboratory developed tests lived under CLIA oversight with FDA enforcement discretion. In May 2024 the FDA published a final rule pulling LDTs into the device framework on a four year, five stage phaseout (ARUP Laboratories, 2024). Companies rewrote roadmaps, investor decks and public statements around device style obligations.

Then the ground moved again. On March 31, 2025, a federal district court in Texas vacated the rule, holding that the FDA had exceeded its authority, and in September 2025 the agency issued a final rule restoring the earlier definition (Sidley Austin, 2025). A Snell and Wilmer analysis of the reversal notes that CLIA remains the primary framework while the long term position stays unsettled (Snell and Wilmer, 2025). Your agency must be able to narrate regulatory change without pretending each turn was predictable.

An agency that sold you certainty in 2024 owes you an apology, not a retainer renewal.

III. Exemplum

The LDT fight is the case study your agency should already know

Watch how the two camps communicated during the rule's life and death. The laboratory associations that prevailed in court argued from statute, history and patient access, publishing detailed explainers that trade press could lift whole: ARUP's FAQ walks through the rule's stages and dates with unusual clarity (ARUP Laboratories, 2024). Their opponents argued from safety incidents and the risks of unreviewed tests marketed at scale.

Notice what the winning side never did. It never claimed its tests needed no oversight. It claimed the oversight belonged to a different statute, and it said so in the same measured tone for two years. Meanwhile the losing side's public problem was not its science. It was a rule whose legal foundation a court dismantled in one ruling. Ask agency candidates which side's discipline they would copy. The answer tells you whether they sell volume or judgment.

Consistency across a two year argument beats cleverness in any single news cycle.

IV. Damnum

Regulatory whiplash charges interest on every confident statement you made

Count what the reversal cost companies that communicated carelessly. Compliance programmes built for device requirements had to be unwound or paused. Marketing written around pending FDA review had to be pulled. Investors who were told the rule would raise barriers against smaller rivals had to be told the opposite, and a LigoLab review of the episode stresses that validation, documentation and inspection readiness under CLIA never stopped mattering during the confusion (LigoLab, 2025).

The deeper cost is tonal. Customers, ordering clinicians and partners remember which companies announced each turn as total victory. A diagnostics brand gets perhaps two episodes of whiplash before its statements stop being quoted at all. Your agency's job is to keep your voice usable across regimes: precise about what is known, explicit about what is pending, silent about what is merely hoped.

Every overclaim is a loan taken against your next announcement, and the interest compounds.

The whiplash also has a payer dimension agencies rarely price in. Coverage policies were rewritten across the industry while the LDT rule lived, and medical policy teams remember which manufacturers briefed them honestly about timelines and which ones sold them a regulatory outcome as settled fact. When your next test seeks coverage, that memory is in the room. A communications partner with genuine payer fluency will be managing your credibility with medical policy staff during quiet periods, not just your visibility during launches. Ask candidates when they last spoke with a payer medical director. The pause before the answer is data.

V. Genus

The variable that decides your coverage is evidence language

Journalists and payers both read your claims against your study designs. The FTC's December 2022 Health Products Compliance Guidance, which replaced the 1998 dietary supplements guide and now covers health products broadly, requires health claims to be truthful, not misleading and substantiated before publication (FoodChain ID, 2023). Diagnostics marketing lives directly under that standard, especially direct to consumer testing sold on outcomes.

Drill candidates on your weakest study. Which population, which comparator, which endpoint, which limitation section. An agency that asks for the limitation section before asking for the press release budget understands this category. One that asks only about your launch date is a events company with a healthcare page on its website.

In diagnostics, the limitation section is part of the pitch. Hide it and someone else will present it.

VI. Regio

Five buyers, five definitions of proof

Segmentation fails in a predictable way in this industry: the patient facing campaign borrows language from the clinician deck, and claims tuned for specialists land in consumer feeds stripped of context. Your agency should show you separate message houses per audience with a shared evidence spine. One spine, five dialects. Anything less produces either confused patients or embarrassed clinicians, and both write emails you will have to answer.

A result explained five ways is still one result. An explanation that shifts with the audience is a liability.

There is a practical way to test whether an agency can actually hold that spine across audiences. Commission a paid pilot before any retainer: one study, rendered three ways, as a clinician briefing, a payer summary and a patient explainer, all from the same data, all to be reviewed by your medical director and your toughest internal critic. Score factual consistency, the handling of limitations, and how the patient version treats a frightened reader whose result is ambiguous. Agencies that pass this test almost always perform in the relationship. Agencies that argue the test is unnecessary are telling you how they handle scrutiny generally, and you should believe them the first time.

VII. Occasio

The open slot is chief explainer of a confused category

Trust in the referee is low, which creates work for honest players. A KFF tracking poll found only 36 percent of adults confident that the FDA acts independently, with similar numbers for other federal health agencies (KFF, 2026). When the public doubts the regulator, it looks for interpreters, and Edelman's 2025 Trust and Health research describes influence decentralising toward local and peer voices rather than national institutions (Edelman, 2025).

That is an opening for the diagnostics company willing to publish plain explainers: what CLIA certification does and does not cover, how validation studies are designed, what a result can and cannot rule out. Almost nobody in your category does this consistently, because it feels like educating the market for competitors. It is. It also makes you the source journalists call when the next rule, recall or outbreak lands, and that call is worth more than a quarter of launch coverage.

When the referee is doubted, the most trusted voice is the player who explains the rules without spinning them.

Start with the questions patients actually type at midnight: what does a positive result mean, what happens next, who sees my data, what does this test miss. A diagnostics company that answers those searches in plain, accurate language builds an asset no rival can discount, because it ranks, it gets quoted by patient communities, and it demonstrates in public exactly the carefulness your clinicians and payers hope you have. Your agency should show you its plan for that library in the first proposal, with the medical review workflow attached.

VIII. Structura

A single laboratory with rigorous habits can out publish a national brand

The structure of this market favours the disciplined. A validation study posted in full, a limitations page that clinicians respect, a medical director who answers trade press questions on the record: these are cheap assets, and they compound. Large testing brands carry legacy claims, legacy marketing and the residue of the Theranos era, a shadow your agency should understand without exploiting. Every diagnostics pitch you will ever hear is graded against that history by someone in the room.

Test candidates with a scenario: a competitor's home test is criticised on social media for false reassurance, and a reporter asks you to comment. The right answer involves your evidence standards, not their failure. Agencies that reach for the knife in a category built on trust will eventually cut you with it.

Your validation binder is a media asset. Treat it like one before someone treats it like evidence.

IX. Consilium

Select for regulatory fluency first, storytelling second

Weight the scorecard toward the failures that end companies in this category, not the ones that merely embarrass them.

The resources library collects the companion healthcare guides, and the services overview explains how a sector engagement is structured. The closest sibling to this guide is the one for medical device manufacturers, whose recall discipline your lab will recognise.

Frequently asked questions

Our test is CLIA certified. Can we say FDA approved in marketing?

No, and an agency that lets that sentence survive a first draft has failed your interview. CLIA certification and FDA clearance or approval are different frameworks with different meanings. The confusion is common in consumer marketing and it is exactly the kind regulators and reporters look for.

How should we talk about the LDT rule now that it was vacated?

Describe the sequence accurately: the 2024 rule, the March 2025 court decision, and the September 2025 reversion, then state your own compliance position under CLIA. Do not declare the question settled forever. Congress and future rulemaking remain live possibilities, and your statements should survive either outcome.

What does a diagnostics agency actually do between launches?

Coverage decisions, guideline conversations, validation explainers, conference positioning, clinician education and monitoring of the oversight debate. If an agency shows you a plan that is silent between product announcements, it does not understand a category where news is made by payers and regulators.

Should we market direct to consumer at all?

Plenty of companies do it well. The conditions are strict: claims substantiated before publication, result interpretation written for a worried reader at midnight, and a clear path from result to clinician. Your agency should be able to show consumer work that passed a hostile legal read.

How do we evaluate an agency's relationships in this space?

Ask which trade titles and lab publications they placed in during the last year, which payer and policy conferences they work, and whether their people can explain your category's coverage fight in two minutes. Named, checkable specifics beat adjectives.

What should we measure after six months?

Quality of explanation in coverage, not volume: correct descriptions of your evidence, inclusion in payer and policy stories, clinician facing placements, and zero claim corrections. A single accurate feature in the titles your buyers read outweighs a pile of syndicated launch releases.

Can one agency handle both our clinician and consumer audiences?

Yes, if it staffs them as separate disciplines with one evidence spine. The failure mode to avoid is a single message house stretched across both, which produces consumer copy that reads like a package insert and clinician copy that reads like an advertisement.

How this guide was built

The regulatory narrative here was assembled from published legal and laboratory analyses of the LDT rule and its reversal, laboratory association explainers, FTC guidance summaries and KFF and Edelman trust research. Two limits deserve stating. The LDT position described is the position as documented through the September 2025 reversion; later legislative or agency action could change it again, which is rather the point of the guide. Survey figures on institutional trust describe the general public, not laboratory professionals, whose confidence patterns differ. Verify the current regulatory position with counsel before you print anything, including this paragraph's summary of it.

X. Incipe

Where Frontier Industries fits in this decision

Frontier Industries builds healthcare communications for companies whose claims get read by regulators as carefully as by customers, and diagnostics is the category where that reading is least forgiving. The team's approach follows the order this guide argues for: evidence language first, audience segmentation second, coverage third. The team page introduces the people behind the work, and the sibling guide for senior care providers covers the audience overlap many testing companies now serve.

If your agency conversations are under way, bring your validation summary and your hardest coverage question to the first call. Bring both to the industry campaign page, or call 401-219-4207 and put the coverage question first.

Sources

1. ARUP Laboratories, The FDA's Final Rule on Laboratory-Developed Tests: FAQs. https://www.aruplab.com/fda-ldt-final-rule/faq 2. Sidley Austin, FDA's Laboratory-Developed Test Rule Struck Down in Major Test of Loper Bright, 2025. https://www.sidley.com/en/insights/newsupdates/2025/04/fdas-laboratory-developed-tests-ldt-rule-struck-down-in-major-test-of-loper-bright 3. Snell and Wilmer, FDA Reverses Final Rule on LDTs: A Win for Labs, a Shift in Regulatory Strategy, 2025. https://www.swlaw.com/publication/fda-reverses-final-rule-on-ldts-a-win-for-labs-a-shift-in-regulatory-strategy 4. LigoLab, The FDA's Final Rule on LDTs and What It Means for Independent Medical Labs. https://www.ligolab.com/post/the-fdas-final-rule-on-ldts-and-what-it-means-for-independent-medical-labs 5. Lab Manager, Clinical PCR Validation: CLIA, CAP, and LDTs. https://www.labmanager.com/qpcr-and-dpcr-in-clinical-diagnostics-validation-under-clia-and-cap-36122 6. Dicentra, FDA Publishes Final Rule on Laboratory Developed Tests (LDTs), 2024. https://dicentra.com/blog/fda/fda-publishes-final-rule-on-laboratory-developed-tests-ldts 7. FoodChain ID, FTC Guidance on Advertising Claims Update, covering the FTC Health Products Compliance Guidance, 2022. https://www.foodchainid.com/resources/united-states-updated-ftc-guidance-on-claims-in-advertising/ 8. Manatt, Phelps and Phillips, FTC Warns Almost 700 Advertisers: Substantiate Your Claims or Face Civil Penalties, 2023. https://www.manatt.com/insights/newsletters/advertising-law/ftc-warns-almost-700-advertisers-substantiate-your 9. KFF, KFF Poll Finds That Most Adults Lack Confidence in Key Health Agencies to Act Independently, 2026. https://www.kff.org/health-information-trust/kff-poll-finds-that-most-adults-lack-confidence-in-key-health-agencies-to-act-independently/ 10. Edelman, Changing the Rules of Health Influence, 2025 Edelman Trust Barometer Special Report: Trust and Health. https://www.edelman.com/trust/2025/trust-barometer/special-report-health/rules-health-influence